Quantcast

Latest Angiogenesis Stories

2014-06-11 08:29:11

INDIANAPOLIS, June 11, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Phase III REACH trial of CYRAMZA(TM) (ramucirumab) in patients with hepatocellular carcinoma, also known as liver cancer, did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant. Encouraging single-agent CYRAMZA activity was observed, with meaningful improvements in key secondary endpoints of progression-free survival, overall...

2014-06-05 12:28:09

Two New Therapies Will Match Progression-Free Survival Improvements Required By Surveyed U.S. Payers for Formulary Inclusion, According to a New Report from Decision Resources Group BURLINGTON, Mass., June 5, 2014 /PRNewswire/ -- Decision Resources Group finds that in addition to an improvement in median overall survival (MOS), delayed disease progression is one of the greatest unmet needs in the first-line treatment of advanced ovarian cancer (CaO). MOS and disease progression are also key...

2014-06-02 20:22:44

-- REVEL Data Published in The Lancet, Presented at Annual ASCO Meeting -- CHICAGO, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from REVEL, a global Phase III study of CYRAMZA((TM)) (ramucirumab) in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC). Data from the trial were published today in The Lancet and also presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract...

2014-05-23 04:20:45

COMBO(TM) Dual Therapy Stent shown to actively promote rapid endothelialization and deliver long-term, true vessel healing HONG KONG, May 23, 2014 /PRNewswire/ -- OrbusNeich today announced long-term results from its REMEDEE Trial. In addition to showing that the COMBO(TM) Dual Therapy Stent shows no late target lesion revascularization, the results demonstrate that the stent proactively promotes functional vessel healing. Key findings include: -...

2014-05-07 09:54:08

Mechanisms of VEGF inhibitor-induced hypertension need to be better understood and guidelines developed to improve management, say researchers in the Canadian Journal of Cardiology New cancer therapies, particularly agents that block vascular endothelial growth factor (VEGF) signaling, have improved the outlook for patients with some cancers and are now used as a first line therapy for some tumors. However, almost 100% of patients who take VEGF inhibitors (VEGFIs) develop high blood...

2014-05-06 16:33:25

MARIETTA, Ga., May 6, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that two of its peer-reviewed scientific studies have been published in the scientific literature. The Company's study "Angiogenic Properties of Dehydrated Human Amnion/Chorion Allografts: Therapeutic Potential for Soft Tissue Repair and...

2014-05-05 23:05:29

Nutrition 21, LLC (“Nutrition 21”) is proud to announce the presentation of a new clinical study supporting Nitrosigine™ inositol-stabilized arginine silicate, titled, “A Clinical Evaluation to Determine the Safety, Pharmacokinetics and Pharmacodynamics of an Inositol-Stabilized Arginine Silicate Dietary Supplement in Healthy Adult Males.” Purchase, NY (PRWEB) May 05, 2014 Nutrition 21, LLC (“Nutrition 21”) is proud to announce the presentation of a new clinical study...

2014-04-23 16:30:05

2014 wound healing research grant awarded to the Wound Healing Society Foundation ORLANDO, Fla., April 23, 2014 /PRNewswire-USNewswire/ -- The Bates-Jensen Wound Reach Foundation and the Angiogenesis Foundation announce Keith Brantly, former U.S. Olympics Marathoner, will run in the Wound Reach Foundation OUCH! Race Friday April 25(th), in Orlando, FL starting at the Gaylord Palms Hotel. Brantley will race four days after competing in the Boston Marathon. The OUCH! Race is a charity...

2014-04-21 20:21:44

INDIANAPOLIS, April 21, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA(TM) (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. With this approval, CYRAMZA becomes the first FDA-approved treatment for patients...

2014-04-16 12:30:22

Advanced Tumor Modeling for Evaluation of Cancer Therapy Efficacy at the Cellular Level MENLO PARK, Calif., April 16, 2014 /PRNewswire/ -- SRI International has announced the availability of its PDCellX(TM) xenograft tumor model services for testing the activity of potential cancer therapeutics. PDCellX models provide clinically relevant information that allows researchers to evaluate the efficacy of cancer drug candidates in new models that go beyond traditional tumor xenograft...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related